Abstract
Epistaxis is a common and a well-known symptom. Nasal packing is an effective treatment in most cases [1]. The COVID-19 disease treatment includes conventional or high flow nasal oxygen therapy and systemic anticoagulation [2]. Patients in intensive care unit may require therapeutic anticoagulation for venous thromboembolism, hyperinflammatory status, extracorporeal membrane oxygenation (ECMO) and multiple other pathologies. The use of therapeutic anticoagulation increases risk of nose bleeding, and its management may be challenging. CAVI-T (Figures 1 & 2) is a new asymmetrical low-pressure balloon that have shown promising results to control epistaxis in emergency. We report herein the management of severe epistaxis in two COVID-19 patients admitted to ICU for severe respiratory failure.
Highlights
Epistaxis is a common and a well-known symptom
We report the management of severe epistaxis in two COVID-19 patients admitted to ICU for severe respiratory failure
A 51-year-old COVID-19 positive male patient admitted to ICU for respiratory failure
Summary
Epistaxis is a common and a well-known symptom. Nasal packing is an effective treatment in most cases [1]. A New Device for Managing Refractory Epistaxis in ICU Patients with COVID-19 The COVID-19 disease treatment includes conventional or high flow nasal oxygen therapy and systemic anticoagulation [2]. CAVI-T (Figures 1 & 2) is a new asymmetrical low-pressure balloon that have shown promising results to control epistaxis in emergency. We report the management of severe epistaxis in two COVID-19 patients admitted to ICU for severe respiratory failure.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
